SNP chips, a type of DNA microarray frequently employed by consumer genomics companies, are "extremely unreliable" when identifying clinically-relevant variants that are rare among the general population, according to a retrospective study recently published in The BMJ.
The investigation, conducted by researchers from the University of Exeter, reviewed sequencing data from nearly 50,000...
Consumer genomics company Ancestry recently received two FDA 510(k)s – one for an in vitro molecular test that detects genomic variants tied to potential disease risk, and another for a saliva-based DNA specimen-collection kit.
Both of these submissions were received by the FDA in October of last year, which officially cleared them on August 13, according to the agency's 510(k) database.
Each was...
23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need for confirmatory testing.
WHAT HAPPENED
This action updates a De Novo approval granted to the consumer genomics company in late 2018. That decision allowed 23andMe to market a test for one of 33...
Consumer genomic company Ancestry, which got its start in providing testing for family history, is launching a new product which features next-generation sequencing. The new product aims to help customers gain insights into their health and risk factors.
Called “AncestryHealth powered by Next Generation Sequencing,” the tool can screen for genes associated with breast cancer, heart disease,...
This morning, direct-to-consumer genomics startup The DNA Company announced its purchase of digital therapeutic My Pain Sensei for roughly $30 million.
The technology from the two companies will be combined to form a new platform called My Next Health, which will use genomic information to help users get insights into preventing and managing chronic conditions.
The DNA Company notes that the...
The last month has been tough going for the consumer genomics industry with frontrunners 23andMe and Ancestory.com both announcing massive layoffs. However, new kid on the block Nebula Genomics is launching a consumer product today that will offer users whole genome sequencing for $299.
“We hope to really revitalize the whole space by making whole genome sequencing affordable, providing more...
23andMe has laid off 100 employees across its consumer business, the genomics company confirmed to MobiHealthNews.
This news come amidst disappointing sales numbers, according to CNBC, which first reported the story. In an interview with CNBC’s Chrissy Farr, 23andMe CEO Anne Wojcicki discussed potential factors contributing to what she sees as a market cooldown, top of the list being customers...
Ancestry, a consumer genomic testing company focused on family history, is now turning to the health space with its launch of AncestryHealth. The new product is aimed at giving customers insights into the health risks associated with their genes and family history.
As part of the new services customers can get tests that are ordered by doctors. The service will also provide education resources...
Genome Medical — a company that offers patient-facing virtual visits and provider-facing consultations with genetic experts — has raised $23 million in Series B funding. The round brings Genome Medical to $46 million in total funding.
The round was led by Echo Health Ventures, with participation from LRVHealth, Casdin Capital, Perceptive Advisors, Manatt Venture Fund and Dreamers Fund, as well as...
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe.
MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...
